2,3-dinor, 6-keto-PGF1alpha

2,3-dinor, 6-keto-pgf1alpha is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 782 references associated with 2,3-dinor, 6-keto-PGF1alpha in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 2,3-dinor, 6-keto-PGF1alpha

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2,3-dinor, 6-keto-PGF1alpha

MeSH term MeSH ID Detail
Hypertension D006973 115 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Carotid Artery Thrombosis D002341 7 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Angina, Unstable D000789 14 associated lipids
Alcoholic Intoxication D000435 15 associated lipids
Ascites D001201 25 associated lipids
Down Syndrome D004314 18 associated lipids
Bartter Syndrome D001477 5 associated lipids
Atherosclerosis D050197 85 associated lipids
Per page 10 20 50 | Total 25

NCBI Entrez Crosslinks

All references with 2,3-dinor, 6-keto-PGF1alpha

Download all related citations
Per page 10 20 50 100 | Total 191
Authors Title Published Journal PubMed Link
Mastrogiannis DS et al. Cocaine decreases urinary prostacyclin release in pregnancy: correlation with uterine and umbilical Doppler velocimetry. 2003 J. Matern. Fetal. Neonatal. Med. pmid:15061316
Saareks V et al. Opposite effects of nicotinic acid and pyridoxine on systemic prostacyclin, thromboxane and leukotriene production in man. 2002 Pharmacol. Toxicol. pmid:12403056
Kudolo GB et al. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects. 2002 Thromb. Res. pmid:12590952
Sinzinger H Comments on "Relationship between thromboxane/prostacyclin ratio and diabetic vascular complications". 2002 Prostaglandins Leukot. Essent. Fatty Acids pmid:12445490
Stichtenoth DO et al. Effects of intravenous oxygen on prostacyclin and thromboxane formation in patients with peripheral occlusive arterial disease. 2001 Prostaglandins Leukot. Essent. Fatty Acids pmid:11728174
Praticò D et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. 2001 Proc. Natl. Acad. Sci. U.S.A. pmid:11248083
Hishinuma T et al. Relationship between thromboxane/prostacyclin ratio and diabetic vascular complications. 2001 Prostaglandins Leukot. Essent. Fatty Acids pmid:11728171
Kaaja R et al. Increased thromboxane production in women with a history of venous thromboembolic event: effect of heparins. 2001 Br. J. Haematol. pmid:11552994
Dowd NP et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. 2001 J. Clin. Invest. pmid:11518732
Belton O et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. 2000 Circulation pmid:10952950
Numminen H et al. The effect of acute ingestion of a large dose of alcohol on the hemostatic system and its circadian variation. 2000 Stroke pmid:10835443
Delemarre FM et al. Urinary prostaglandin excretion in pregnancy: the effect of dietary sodium restriction. 2000 Prostaglandins Leukot. Essent. Fatty Acids pmid:11049696
Brown NJ et al. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. 2000 Circulation pmid:11056091
Tsikas D et al. Solid- and liquid-phase extraction for the gas chromatographic-tandem mass spectrometric quantification of 2,3-dinor-thromboxane B2 and 2,3-dinor-6-oxo-prostaglandin F1 alpha in human urine. 2000 J Chromatogr A pmid:10941682
McAdam BF et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:9874808
Morrow JD et al. Increased formation of thromboxane in vivo in humans with mastocytosis. 1999 J. Invest. Dermatol. pmid:10417625
Tanaka H et al. Can urinary eicosanoids be a potential predictive marker of clinical response to thromboxane A2 receptor antagonist in asthmatic patients? 1999 Respir Med pmid:10653051
Mizugaki M et al. Monitoring of the thromboxane A2/prostacyclin ratio in the urine of patients with retinal vascular occlusion through the low-dose-aspirin therapy using the gas chromatography/selected ion monitoring method. 1999 Prostaglandins Other Lipid Mediat. pmid:10593167
Hishinuma T et al. Urinary thromboxane A2/prostacyclin balance reflects the pathological state of a diabetic. 1999 Prostaglandins Other Lipid Mediat. pmid:10593168
Hoch B and Bernhard M Reduced prostacyclin to thromboxane A2 ratio is correlated with central apneas in preterm infants. 1999 Prostaglandins Other Lipid Mediat. pmid:10593170